骨粗鬆症治療薬の世界市場2015-2019...市場調査レポートについてご紹介

【英文タイトル】Global Osteoporosis Drugs Market 2015-2019

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Disease Overview
06.1 Understanding Osteoporosis
06.2 Epidemiology and Demography
06.3 Risk Factors
06.4 Symptoms
06.5 Diagnosis
06.6 Treatment

07.Key Development in Osteoporosis Therapy

08.Market Landscape
08.1 Market Overview
08.1.1 Market Size and Forecast
08.2 Osteoporosis Drugs Market in US
08.2.1 Market Size and Forecast
08.3 Osteoporosis Drugs Market in Europe
08.3.1 Market Size and Forecast
08.4 Five Forces Analysis

09.Market Segmentation by Therapeutic Class
09.1 Global Osteoporosis Drugs Market by Therapeutic Class 2014-2019
09.2 Antiresorptive Medications
09.3 Anabolic Medications

10.Market Segmentation by Line of Therapy
10.1 Global Osteoporosis Drugs Market by Line of Therapy

11.Pipeline Assessment
11.1 Key Information about Pipeline Candidates

12.Geographical Segmentation
12.1 Global Osteoporosis Drugs Market by Geographical Segmentation 2014-2019
12.2 Osteoporosis Drugs Market in Americas
12.2.1 Market Size and Forecast
12.3 Osteoporosis Drugs Market in EMEA
12.3.1 Market Size and Forecast
12.4 Osteoporosis Drugs Market in APAC
12.4.1 Market Size and Forecast

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.1.3 Vendor Ranking 2014
20.1.4 Competitive Assessment of Major Drugs
20.1.5 Amgen
20.1.6 Eli Lilly
20.1.7 Merck
20.1.8 Novartis
20.2 Other Prominent Vendors

21.Key Vendor Analysis
21.1 Amgen
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation by Revenue 2013
21.1.4 Product Portfolio by Revenue 2013
21.1.5 Business Segmentation by Revenue 2012 and 2013
21.1.6 Geographical Segmentation by Revenue 2013
21.1.7 Business Strategy
21.1.8 Recent Developments
21.1.9 SWOT Analysis
21.2 Eli Lilly
21.2.1 Key Facts
21.2.2 Business Overview
21.2.3 Business Segmentation by Revenue
21.2.4 Sales by Geography
21.2.5 Business Strategy
21.2.6 Key Information
21.2.7 SWOT Analysis
21.3 Merck & Co. Inc.
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation by Revenue 2013
21.3.4 Business Segmentation by Revenue 2012 and 2013
21.3.5 Sales by Geography
21.3.6 Business Strategy
21.3.7 Key Developments
21.3.8 SWOT Analysis
21.4 Novartis AG
21.4.1 Key Facts
21.4.2 Business Description
21.4.3 Business Segmentation
21.4.4 Revenue by Business Segmentation
21.4.5 Revenue Comparison 2012 and 2013
21.4.6 Sales by Geography
21.4.7 Business Strategy
21.4.8 Key Developments
21.4.9 SWOT Analysis

22.Other Reports in this Series
List Of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Interpretation of BMD Results
Exhibit 3: Global Osteoporosis Drugs Market 2014-2019 ($ billion)
Exhibit 4: Osteoporosis Drugs Market in US 2014-2019 ($ billion)
Exhibit 5: Osteoporosis Drugs Market in Europe 2014-2019 ($ billion)
Exhibit 6: Segmentation of Global Osteoporosis Drugs Market by Geography 2014
Exhibit 7: Segmentation of Global Osteoporosis Drugs Market by Geography 2019
Exhibit 8: Osteoporosis Drugs Market in Americas 2014-2019 ($ billion)
Exhibit 9: Osteoporosis Drugs Market in EMEA 2014-2019 ($ billion)
Exhibit 10: Osteoporosis Drugs Market in APAC 2014-2019 ($ billion)
Exhibit 11: Segmentation of Global Osteoporosis Drugs Market by Geography 2014-2019
Exhibit 12: Revenue Comparison of Top Osteoporosis Drugs for First Three Quarters 2014 ($ million)
Exhibit 13: YoY Growth Rate and Global Revenue of Prolia 2010-2013 ($ million)
Exhibit 14: Revenue of Prolia by Country/Region 2010-2013 ($ million)
Exhibit 15: YoY Growth Rate and Global Revenue of Evista 2010-2013 ($ million)
Exhibit 16: Revenue of Evista by Country/Region 2010-2013 ($ million)
Exhibit 17: YoY Growth Rate and Global Revenue of Forteo 2010-2013 ($ million)
Exhibit 18: Revenue of Forteo by Country/Region 2010-2013 ($ million)
Exhibit 19: YoY Growth Rate and Global Revenue of Fosamax 2011-2014 ($ million)
Exhibit 20: YoY Growth Rate and Global Revenue of Reclast/Aclasta 2010-2013 ($ million
Exhibit 21: Revenue of Reclast/Aclasta by Country/Region 2010-2012 ($ million)
Exhibit 22: Amgen: Business Segmentation by Revenue 2013
Exhibit 23: Amgen: Product Portfolio by Revenue 2013
Exhibit 24: Amgen: Business Segmentation by Revenue 2012 and 2013 ($ billion)
Exhibit 25: Amgen: Geographical Segmentation by Revenue 2013
Exhibit 26: Eli Lilly: Business Segmentation by Revenue 2013
Exhibit 27: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ million)
Exhibit 28: Eli Lilly: Sales by Geography 2013
Exhibit 29: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 30: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 ($ billion)
Exhibit 31: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 32: Novartis AG: Business Segmentation
Exhibit 33: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 34: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
Exhibit 35: Novartis AG: Revenue by Geographical Segmentation 2013


【レポート販売概要】

■ タイトル:骨粗鬆症治療薬の世界市場2015-2019
■ 英文:Global Osteoporosis Drugs Market 2015-2019
■ 発行日:2015年5月6日
■ 調査会社:Technavio
■ 商品コード:IRTNTR5759
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。